# Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

> **NCT01413191** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Ciliary Body and Choroid Melanoma, Medium/Large Size
- Ciliary Body and Choroid Melanoma, Small Size
- Iris Melanoma
- Metastatic Intraocular Melanoma
- Recurrent Intraocular Melanoma
- Stage IV Intraocular Melanoma

## Interventions

- **BIOLOGICAL:** Cixutumumab
- **OTHER:** Laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01413191
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-03
- **Final completion:** 2014-06
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2020-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01413191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01413191, "Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01413191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*